'We're good to go': MyoKar­dia clinch­es cru­cial PhI­II win, boost­ing ge­net­ic ap­proach to car­dio R&D

MyoKar­dia said its lead drug has de­liv­ered a clean sweep in a Phase III tri­al, val­i­dat­ing its ground­break­ing idea for bring­ing pre­ci­sion med­i­cine to car­diomy­opathies …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER